Stock Ratings / Health Care / EOCN / dividends

CVKD (40) SXTP (50) GRI (38) ERNA (46) ⌘ Pro Terminal →

Eocene Ltd. (EOCN) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.22 +0.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Eocene Ltd. (EOCN) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $3.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EOCN)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EOCN)

✓Walkthrough of EOCN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EOCN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.39%▼ DESCENDING CHANNEL

2026-10-30O $3.08H $3.39L $3.07C $3.22VOL 3.1K

RES: $4.63SUP: $1.97SMA50: $3.57SMA200: $4.59

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EOCN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EOCN Butterfly Map → + Track EOCN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EOCN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EOCN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EOCN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EOCN)

Health Care Rank #432 of 1016 ⚔️ CVKD vs EOCN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EOCN vs. CVKD, SXTP, GRI, ERNA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Eocene Ltd. (EOCN) ranks #432 by composite RQD confidence (47/100, grade D) and #975 by equity capitalization ($3.4M). Within this direct 5-issuer industry benchmark cohort, EOCN leads on earnings valuation at N/A trailing P/E, while EOCN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SXTP currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with EOCN at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EOCN ACTIVE Eocene Ltd.	D	47/100	—	—	-35.0%	+0.62%	$3.4M	Benchmark Subject
CVKD Cadrenal Therapeutics Inc.	D-	40/100	—	—	-35.0%	-0.47%	$3.4M	/cvkd-vs-eocn →
SXTP 60 Degrees Pharmaceuticals Inc.	D	50/100	—	22.3%	-35.0%	+11.87%	$3.3M	/sxtp-vs-eocn →
GRI GRI Bio Inc.	D-	38/100	—	—	-35.0%	-3.38%	$3.4M	/gri-vs-eocn →
ERNA Ernexa Therapeutics Inc.	D	46/100	—	—	-35.0%	+6.57%	$3.4M	/erna-vs-eocn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001595353

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eocene Ltd. (EOCN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$10.3M, operating cash flow of -$6.3M, and free cash flow of -$6.3M (-7.4% YoY). On the balance sheet, EOCN closed FY2025 with $18.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$10.3M	-$6.3M	-$6.3M	$18.6M	—
FY2024 (FY)	2024-12-31	$0	-$7.5M	-$5.9M	-$5.9M	$18.5M	—
FY2023 (FY)	2023-12-31	$0	-$6.9M	-$6.1M	-$6.1M	—	—

3. EOCN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EOCN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Eocene Ltd. (NASDAQ: EOCN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $3.22 (+0.62% 1D, market cap $3.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, EOCN ranks #432 in composite RQD confidence.

How does EOCN compare to CVKD and SXTP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EOCN carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CVKD (Cadrenal Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and SXTP (60 Degrees Pharmaceuticals Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M). Among the 5-stock peer group, EOCN leads on earnings multiple (N/A) while EOCN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EOCN?

Per EOCN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001595353), Eocene Ltd. generated $0 in revenue, -$10.3M in net income, and -$6.3M in free cash flow against $18.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EOCN trading relative to its 50-day, 200-day, and 52-week technical levels?

EOCN last traded at $3.22 (+0.62% on volume of 6,762 shares), positioning the stock -9.80% below its 50-day simple moving average ($3.57) and -29.85% below its 200-day simple moving average ($4.59). Across its 52-week range of $2.33 to $12.32, EOCN sits at the 8.9% percentile with a 14-day RSI of 43.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.82 to $3.62).

EOCN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does EOCN pay a dividend and is it safe?

Eocene Ltd. (EOCN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: EOCN RQD Cockpit EOCN 12M Forecast EOCN Earnings & Move EOCN Dividends & DRIP EOCN Insiders & 13F EOCN Whale Options EOCN Profit Sankey EOCN News & Why